Literature DB >> 21959367

Limbal stem cell deficiency and ocular phenotype in ectrodactyly-ectodermal dysplasia-clefting syndrome caused by p63 mutations.

Enzo Di Iorio1, Stephen B Kaye, Diego Ponzin, Vanessa Barbaro, Stefano Ferrari, Elisabetta Böhm, Paola Nardiello, Giuseppe Castaldo, John A McGrath, Colin E Willoughby.   

Abstract

OBJECTIVE: To describe the ocular phenotype in patients with ectrodactyly-ectodermal dysplasia-clefting (EEC) syndrome (MIM#604292) and to determine the pathogenic basis of visual morbidity.
DESIGN: Retrospective case series. PARTICIPANTS: Nineteen families (23 patients) affected by EEC syndrome from the United Kingdom, Ireland, and Italy.
METHODS: General medical examination to fulfill the diagnostic criteria for EEC syndrome and determine the phenotypic severity. Mutational analysis of p63 was performed by polymerase chain reaction-based bidirectional Sanger sequencing. All patients with EEC syndrome underwent a complete ophthalmic examination and ocular surface assessment. Limbal stem cell deficiency (LSCD) was diagnosed clinically on the basis of corneal conjunctivalization and anatomy of the limbal palisades of Vogt. Impression cytology using immunofluorescent antibodies was performed in 1 individual. Histologic and immunohistochemical analyses were performed on a corneal button and corneal pannus from 2 EEC patients. MAIN OUTCOME MEASURES: The EEC syndrome phenotypic severity (EEC score), best-corrected Snellen visual acuity (decimal fraction), slit-lamp biomicroscopy, tear function index, tear breakup time, LSCD, p63 DNA sequence variants, impression cytology, and corneal histopathology.
RESULTS: Eleven heterozygous missense mutations in the DNA binding domain of p63 were identified in all patients with EEC syndrome. All patients had ocular involvement and the commonest was an anomaly of the meibomian glands and lacrimal drainage system defects. The major cause of visual morbidity was progressive LSCD, which was detected in 61% (14/23). Limbal stem cell deficiency was related to advancing age and caused a progressive keratopathy, resulting in a dense vascularized corneal pannus, and eventually leading to visual impairment. Histologic analysis and impression cytology confirmed LSCD.
CONCLUSIONS: Heterozygous p63 mutations cause the EEC syndrome and result in visual impairment owing to progressive LSCD. There was no relationship of limbal stem cell failure with the severity of EEC syndrome, as classified by the EEC score, or the underlying molecular defect in p63. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any of the materials discussed in this article.
Copyright © 2012 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21959367     DOI: 10.1016/j.ophtha.2011.06.044

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  28 in total

Review 1.  Corneal changes in ectrodactyly-ectodermal dysplasia-cleft lip and palate syndrome: case series and literature review.

Authors:  Anthony F Felipe; Azin Abazari; Kristin M Hammersmith; Christopher J Rapuano; Parveen K Nagra; Baltasar Moratal Peiro
Journal:  Int Ophthalmol       Date:  2012-05-23       Impact factor: 2.031

2.  The Palisades of Vogt in Congenital Corneal Opacification (An American Ophthalmological Society Thesis).

Authors:  Ken K Nischal; Kira L Lathrop
Journal:  Trans Am Ophthalmol Soc       Date:  2016-08

3.  Personalized Stem Cell Therapy to Correct Corneal Defects Due to a Unique Homozygous-Heterozygous Mosaicism of Ectrodactyly-Ectodermal Dysplasia-Clefting Syndrome.

Authors:  Vanessa Barbaro; Annamaria Assunta Nasti; Paolo Raffa; Angelo Migliorati; Patrizia Nespeca; Stefano Ferrari; Elisa Palumbo; Marina Bertolin; Claudia Breda; Francesco Miceli; Antonella Russo; Luciana Caenazzo; Diego Ponzin; Giorgio Palù; Cristina Parolin; Enzo Di Iorio
Journal:  Stem Cells Transl Med       Date:  2016-05-05       Impact factor: 6.940

4.  Global Consensus on Definition, Classification, Diagnosis, and Staging of Limbal Stem Cell Deficiency.

Authors:  Sophie X Deng; Vincent Borderie; Clara C Chan; Reza Dana; Francisco C Figueiredo; José A P Gomes; Graziella Pellegrini; Shigeto Shimmura; Friedrich E Kruse
Journal:  Cornea       Date:  2019-03       Impact factor: 2.651

5.  Molecular markers for corneal epithelial cells in larval vs. adult Xenopus frogs.

Authors:  Surabhi Sonam; Jennifer A Srnak; Kimberly J Perry; Jonathan J Henry
Journal:  Exp Eye Res       Date:  2019-04-11       Impact factor: 3.467

6.  Preliminary report on screening IGSF3 gene mutation in families with congenital absence of lacrimal puncta and canaliculi.

Authors:  Fei Wang; Hai Tao; Cui Han; Fang Bai; Peng Wang; Xi-Bin Zhou; Li-Hua Wang; Chuan Liu
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

Review 7.  The diagnosis of limbal stem cell deficiency.

Authors:  Qihua Le; Jianjiang Xu; Sophie X Deng
Journal:  Ocul Surf       Date:  2017-11-04       Impact factor: 5.033

8.  Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.

Authors:  Ruby Shalom-Feuerstein; Laura Serror; Edith Aberdam; Franz-Josef Müller; Hans van Bokhoven; Klas G Wiman; Huiqing Zhou; Daniel Aberdam; Isabelle Petit
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-25       Impact factor: 11.205

Review 9.  Stability of limbal stem cell deficiency after mechanical and thermal injuries in mice.

Authors:  Neda Afsharkhamseh; Asadolah Movahedan; Sanaz Gidfar; Michael Huvard; Lisa Wasielewski; Behrad Y Milani; Medi Eslani; Ali R Djalilian
Journal:  Exp Eye Res       Date:  2015-12-01       Impact factor: 3.467

Review 10.  Limbal stem cells: identity, developmental origin, and therapeutic potential.

Authors:  Gabriel Gonzalez; Yuzuru Sasamoto; Bruce R Ksander; Markus H Frank; Natasha Y Frank
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2017-11-03       Impact factor: 5.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.